Skip to main content
REMEVi
ENES
What REMEVi offers

MOTS-c side effects: what is known and what is not

Reported in people, reported in animals, and unknown.

MOTS-c’s side effects in people are poorly described because no completed human trial of MOTS-c exists. An early trial of a related molecule reported injection-site reactions most often; online buyers report other effects. MOTS-c is not FDA-approved, and REMEVi does not currently offer it. Nobody can call it safe or unsafe for you without a licensed provider’s review.

MOTS-c is not FDA-approved. Since HHS’s October 2026 interim policy, a state-licensed 503A pharmacy may compound it on a patient-specific prescription under listed conditions.

REMEVi does not currently offer MOTS-c.

Reported in people

USADA states there are no completed human clinical trials of MOTS-c, so no controlled side-effect data exist for MOTS-c itself. Two other sources give partial pictures:

  • CB4211, an analog of MOTS-c (a different molecule): in a company-sponsored Phase 1a/1b study, the company reported no serious adverse events, and the adverse events seen in more than 10% of treated participants were transient, mostly mild to moderate injection-site reactions. This was a press release, not a peer-reviewed paper.
  • People who say they bought MOTS-c online have reported, per USADA, a faster heart rate or palpitations, injection-site irritation, insomnia, local or whole-body immune reactions, and fever. These are self-reports, not trial data.

Reported in animal studies

The mouse studies (Lee 2015, Reynolds 2021) were designed to measure insulin response, glucose handling and physical performance, not to build a side-effect profile. They do not tell us how often a given side effect would appear in people.

What is unknown

  • How often any side effect happens in people taking MOTS-c, at any dose.
  • Effects of long-term use; USADA notes there are no data on long-term use.
  • Interactions with other medicines. Mouse studies looked at glucose handling, so tell your provider about any diabetes medicine.
  • Effects during pregnancy or breastfeeding.

Injection-site effects

Injection-site reactions such as redness, irritation or swelling were the most common adverse event in the CB4211 analog trial and appear in self-reports. Use a new sterile syringe each time. Contact your provider about spreading redness, warmth, pus or fever, and get emergency care for swelling of the face or trouble breathing.

Who should not use MOTS-c without a provider’s review

  • People who are pregnant, trying to conceive or breastfeeding.
  • Anyone under 18.
  • People with active cancer or a history of cancer — tell your provider.
  • Anyone with a known allergy to MOTS-c or to an ingredient in the product.
  • Anyone taking other medicines or supplements — share the full list with your provider.
  • Athletes subject to drug testing: MOTS-c is prohibited at all times, according to USADA.

Product quality is a side-effect question too

“Research use only” MOTS-c vials are outside the HHS policy: no named patient and no requirement for a registered source or certificate of analysis. FDA sent warning letters to five online peptide vendors on August 24, 2026.

How to report a side effect

Under the policy, serious adverse events from compounded MOTS-c are reported to FDA MedWatch. You or your provider can file a report directly.

Report to FDA MedWatch

Is MOTS-c safe to inject?

There is not enough evidence to answer that. MOTS-c has no completed human trials, so its risks in people are unknown, and it is not FDA-approved. A related molecule’s early trial reported injection-site reactions most often. A licensed provider can weigh your history and medicines; report any serious reaction to FDA MedWatch.

Sources

  1. USADA — What is the MOTS-c peptide? (read November 2, 2026)
  2. CohBar press release (via BioSpace), Aug 10, 2021 — Positive topline results from the Phase 1a/1b study of CB4211, an analog of MOTS-c (company-reported, not peer-reviewed) (read November 2, 2026)
  3. Lee et al., Cell Metabolism 2015 — The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance (read November 2, 2026)
  4. Reynolds et al., Nature Communications 2021 — MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis (read November 2, 2026)
  5. HHS, Federal Register — Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (91 FR 68526, October 30, 2026) (read November 2, 2026)
  6. Holtz, Beaver & Rosen (Foley & Lardner), National Law Review, Oct 30, 2026 — HHS Announces Limited Enforcement Discretion for Compounding of Six Peptides (read November 2, 2026)
  7. Holland & Knight, Oct 16, 2026 — Peptides at a Crossroads: What Wellness Providers Need to Know About HHS and FDA Actions (read November 2, 2026)
  8. FDA — MedWatch: The FDA Safety Information and Adverse Event Reporting Program (read November 2, 2026)

Medically reviewed by Linda West-Conforti, RN · CA RN #389453 ·